Profile
Malken Bayrakdarian currently works as an Executive Director at NuChem Sciences, Inc.
Malken Bayrakdarian active positions
| Companies | Position | Start |
|---|---|---|
NuChem Sciences, Inc.
 NuChem Sciences, Inc. BiotechnologyHealth Technology Part of Sygnature Discovery Ltd., NuChem Sciences, Inc. was founded in 2011 and is a leading contract research organization in drug discovery and chemical development. The company is based in Saint-Laurent, Canada. NuChem Sciences, which employs 300 scientific and support staff, offers a range of standalone and integrated discovery services in chemistry, biochemistry, in-vitro biology, DMPK, structural biology, and in vivo pharmacology. NuChem Sciences' expert chemistry services for drug discovery feature synthetic, medicinal, and analytical solutions. The Canadian company also offers advanced ADME studies, metabolic stability analysis, and tailored solutions for drug discovery. NuChem Sciences was acquired by Sygnature Discovery Ltd. on July 31, 2023. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
NuChem Sciences, Inc.
NuChem Sciences, Inc. BiotechnologyHealth Technology Part of Sygnature Discovery Ltd., NuChem Sciences, Inc. was founded in 2011 and is a leading contract research organization in drug discovery and chemical development. The company is based in Saint-Laurent, Canada. NuChem Sciences, which employs 300 scientific and support staff, offers a range of standalone and integrated discovery services in chemistry, biochemistry, in-vitro biology, DMPK, structural biology, and in vivo pharmacology. NuChem Sciences' expert chemistry services for drug discovery feature synthetic, medicinal, and analytical solutions. The Canadian company also offers advanced ADME studies, metabolic stability analysis, and tailored solutions for drug discovery. NuChem Sciences was acquired by Sygnature Discovery Ltd. on July 31, 2023. | Health Technology |
- Stock Market
- Insiders
- Malken Bayrakdarian
